Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

argenx SE

ARGX:BRU

argenx SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)334.60
  • Today's Change-5.30 / -1.56%
  • Shares traded39.20k
  • 1 Year change-13.36%
  • Beta0.5774
Data delayed at least 15 minutes, as of May 20 2024 16:39 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 16-May-24
Select bar for recommendation details.
Recommendations16-May-24
Buy3
Outperform11
Hold5
Underperform0
Sell1

Share price forecast in USD

The 17 analysts offering 12 month price targets for argenx SE have a median target of 470.43, with a high estimate of 600.55 and a low estimate of 155.14. The median estimate represents a 40.59% increase from the last price of 334.60.
High79.5%600.55
Med40.6%470.43
Low-53.6%155.14

Dividends

Dividend information is not available for argenx SE.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On May 09, 2024, argenx SE reported 1st quarter 2024 losses of -1.04 per share.
The next earnings announcement is expected on Jul 25, 2024.
Average growth rate-48.82%
argenx SE reported annual 2023 losses of -5.16 per share on Feb 29, 2024.
Average growth rate-40.29%
More ▼

Revenue history & estimates in USD

argenx SE had 1st quarter 2024 revenues of 412.51m. This bettered the 405.74m consensus of the 17 analysts covering the company. This was 79.54% above the prior year's 1st quarter results.
Average growth rate+16.23%
argenx SE had revenues for the full year 2023 of 1.27bn. This was 184.91% above the prior year's results.
Average growth rate+211.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.